Algorithm for Early Diagnosis of Contrast-Induced Nephropathy Using Biomarkers of Renal Damage

The aim of the study was to develop an algorithm for early diagnosis of contrast-induced nephropathy using renal damage biomarkers cystatin C, nephrin and lipocalin 2.

Materials and Methods. Eighty-four patients, who for the first time underwent transcutaneous coronary intervention with radiocontrast agents, were included in the study. Group 1 was composed of patients with diabetes mellitus type 2 (n=44), group 2 consisted of patients without carbohydrate metabolism impairment (n=40). All patients were determined the concentration of renal damage biomarkers before and after the procedure.

Results. Cystatin C, nephrin and lipocalin 2 have been established to have high sensitivity and specificity. Determining them for 3 days enables objective assessment of the contrast-induced nephropathy dynamics. The proposed algorithm with biomarker application makes it possible to predict the development of acute renal insufficiency during operative interventions on the coronary arteries with introduction of contrast agents, and to carry out preventive therapy and intensive rehydration.

1. Brown J.R., DeVries J.T., Piper W.D., Robb J.F., Hearne M.J., Ver Lee P.M., Kellet M.A., Watkins M.W., Ryan T.J., Silver M.T., Ross C.S., MacKenzie T.A., O’Connor G.T., Malenka D.J. Serious renal dysfunction after percutaneous coronary interventions can be predicted. Am Heart J 2008; 155(2): 260–266, https://doi.org/10.1016/j.ahj.2007.10.007.
2. Mehran R., Aymong E.D., Nikolsky E., Lasic Z., Iakovou I., Fahy M., Mintz G.S., Lansky A.J., Moses J.W., Stone G.W., Leon M.B., Dangas G. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004; 44(7): 1393–1399, https://doi.org/10.1016/s0735-1097(04)01445-7.
3. Lee P.T., Chou K.J., Liu C.P., Mar G.Y., Chen C.L., Hsu C.Y., Fang H.C., Chung H.M. Renal protection for coronary angiography in advanced renal failure patients by prophylactic hemodialysis. A randomized controlled trial. J Am Coll Cardiol 2007; 50(11): 1015–1020, https://doi.org/10.1016/j.jacc.2007.05.033.
4. Domoradskaya A.I. Contrast-induced nephropathy: risk factors. Russian Electronic Journal of Radiology 2011; 4: 27–32.
5. Toprak O. Risk markers for contrast-induced nephropathy. Am J Med Sci 2007; 334: 283–290, https://doi.org/10.1097/maj.0b013e318068ddf9.
6. Mironova O.Yu. Contrast-induced nephropathy. Terapevticheskii arkhiv 2013; 85(6): 90–95.
7. Volgina G.V. Contrast-induced nephropathy: pathogenesis, risk factors, prevention strategies (Part II). Nefrologiya i dializ 2006; 8(2): 176–183.
8. McCullough P.A., Adam A., Becker C.R., Davidson C., Lameire N., Stacul F., Tumlin J. Risk prediction of contrast-induced nephropathy. Am J Cardiol 2006; 98(6): 27–36, https://doi.org/10.1016/j.amjcard.2006.01.022.
9. Rudnick M., Feldman H. Contrast-induced nephropathy: what are the true clinical consequences? Clin J Am Soc Nephrol 2008; 3(1): 263–272, https://doi.org/10.2215/cjn.03690907.
10. Aspelin P., Aubry P., Fransson S.G., Strasser R., Willenbrock R., Berg K.J. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003; 348(6): 491–499, https://doi.org/10.1056/nejmoa021833.
11. KDIGO 2012 clinical practice guideline for acute kidney injury. Kidney International 2012; 2(Suppl 1): 1–141.
12. Newhouse J.H., Kho D., Rao Q.A., Starren J. Frequency of serum creatinine changes in the absence of iodinated contrast material: implications for studies of contrast nephrotoxicity. AJR Am J Roentgenol 2008; 191(2): 376–382, https://doi.org/10.2214/ajr.07.3280.
13. Bartholomew B.A., Harjai K.J., Dukkipati S., Boura J.A., Yerkey M.W., Glazier S., Grines C.L., O’Neill W.W. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol 2004; 93(12): 1515–1519, https://doi.org/10.1016/j.amjcard.2004.03.008.
14. James M.T., Ghali W.A., Knudtson M.L., Ravani P., Tonelli M., Faris P., Pannu N., Manns B.J., Klarenbach S.W., Hemmelgarn B.R.; Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators. Associations between acute kidney injury and cardiovascular and renal outcomes after coronary angiography. Circulation 2011; 123(4): 409–416, https://doi.org/10.1161/circulationaha.110.970160.
15. Kobalava Zh.D., Villeval’de S.V., Efremovtseva M.A., Moiseev V.S. Biomarkers of acute kidney injury: current views and prospects. Terapevticheskii arkhiv 2014; 86(6): 88–93.
16. Parfrey P.S., Griffiths S.M., Barrett B.J., Paul M.D., Genge M., Withers J., Farid N., McManamon P.J. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med 1989; 320(3): 143–149, https://doi.org/10.1056/nejm198901193200303.
17. Dedov I.I., Shestakova M.V., Mayorov A.Y., Vikulova O.K., Galstyan G.R., Kuraeva T.L., Peterkova V.A., Smirnova O.M., Starostina E.G., Surkova E.V., Sukhareva O.Y., Tokmakova A.Y., Shamkhalova M.S., Jarek-Martynova I.R., Beshlieva D.D., Bondarenko O.N., Volevodz N.N., Grigoryan O.R., Esayan R.M., Ibragimova L.I., Kalashnikov V.Y., Lipatov D.V., Shestakova E.A. Standards of specialized diabetes care (8th edition). M.V. Shestakova, A.Y. Mayorov (editors). Diabetes mellitus 2017; 20(1S): 1–112, https://doi.org/10.14341/dm20171s8.
18. Yarkova N.А., Borovkov N.N., Zanozina О.V., Nosov V.P. Cystatin C in the diagnosis of chronic kidney disease in patients with type 2 diabetes mellitus. Sovremennye tehnologii v medicine 2013; 5(4): 89–93.
19. Rudnick M.R., Goldfarb S., Tumlin J. Contrast-induced nephropathy: is the picture any clearer? Clin J Am Soc Nephrol 2008; 3(1): 261–262.
20. Immunokhimicheskiy analiz v laboratornoy meditsine [Immunochemical analysis in laboratory medicine]. Pod red. Dolgova V.V. [Dolgov V.V. (editor)]. Moscow–Tver: OOO “Izdatel’stvo “Triada”; 2015; 418 p.
21. Yarkova N.A. Nephrin — early marker of kidney disorder in the case of diabetes mellitus of the 2nd type. Meditsinskiy al’manakh 2017; 2(47): 101–103.
22. Aspelin P., Aubry P., Fransson S.G., Strasser R., Willenbrock R., Berg K.J. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003; 348(6): 491–499, https://doi.org/10.1056/nejmoa021833.
23. Vervoort G., Willems H.L., Wetzels J.F. Assessment of glomerular filtration rate in healthy subjects and and normoalbuminuric diabetic patients: validity of a new (MDRD) prediction equation. Nephrol Dial Transplant 2002; 17(11): 1909–1913, https://doi.org/10.1093/ndt/17.11.1909.
24. Mehran R., Aymong E.D., Nikolsky E., Lasic Z., Iakovou I., Fahy M., Mintz G.S., Lansky A.J., Moses J.W., Stone G.W., Leon M.B., Dangas G. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004; 44(7): 1393–1399, https://doi.org/10.1016/s0735-1097(04)01445-7.
25. Solomon R.J., Mehran R., Natarajan M.K., Doucet S., Katholi R.E., Staniloae C.S., Sharma S.K., Labinaz M., Gelormini J.L., Barrett B.J. Contrast-induced nephropathy and long-term adverse events: cause and effect? Clin J Am Soc Nephrol 2009; 4(7): 1162–1169, https://doi.org/10.2215/cjn.00550109.

Yarkova N.A., Borovkov N.N. Algorithm for Early Diagnosis of Contrast-Induced Nephropathy Using Biomarkers of Renal Damage. Sovremennye tehnologii v medicine 2017; 9(4): 156, https://doi.org/10.17691/stm2017.9.4.19